Valuation: Immutep Limited

Market Cap 81.05M 56.21M 49.19M 45.34M 42.02M 79.77M 5.34B 544M 211M 2.63B 211M 206M 9.1B P/E 2026 *
-1.4x
P/E 2027 * -1.99x
Enterprise Value 15.96M 11.07M 9.69M 8.93M 8.28M 15.71M 1.05B 107M 41.64M 519M 41.57M 40.67M 1.79B EV / Sales 2026 *
0.93x
EV / Sales 2027 * 1.2x
Free-Float
96.98%
Yield 2026 *
-
Yield 2027 * -
1 day-3.64%
1 month+12.77%
3 months+20.45%
6 months-87.67%
Current year-87.23%
1 week 0.05
Extreme 0.052
0.06
1 month 0.04
Extreme 0.044
0.06
Current year 0.03
Extreme 0.028
0.47
1 year 0.03
Extreme 0.028
0.47
3 years 0.03
Extreme 0.028
0.48
5 years 0.03
Extreme 0.028
0.71
10 years 0.03
Extreme 0.028
0.72
Manager TitleAgeSince
Chief Executive Officer 53 09/07/2014
Director of Finance/CFO - 01/03/2018
Chief Tech/Sci/R&D Officer - 01/07/2025
Director TitleAgeSince
Director/Board Member 53 09/07/2014
Chairman 76 17/11/2017
Director/Board Member 57 12/02/2014
Date Insider Type Main position Quantity % Market Cap.
03-18Other

Chief Technology Officer

14,224,374 0.9652%
03-18Other

Chairman

3,091,623 0.2098%
03-18Other

Chief Executive Officer

18,477,395 1.2538%
Change 5-day change 1-year change 3-year change Capi.($)
-3.64%0.00%-78.80%-82.90% 56.21M
+0.02%+5.09%+2.80%+9.26% 49.74B
+0.39%+1.70%+419.39%+621.71% 40.49B
-2.28%+8.42%+28.20%+63.00% 34.35B
-1.92%+7.77%+28.18%-3.96% 34.75B
+1.31%-0.56%+5.12%+33.90% 26.98B
+0.20%+0.09% - - 16.58B
-2.67%+3.15%+71.30%+131.94% 15.6B
-0.71%+8.88%+106.63%+106.63% 14.27B
-2.47%-1.84%+12.60%+18.02% 13.76B
Average -1.25%+4.17%+66.16%+99.73% 24.66B
Weighted average by Cap. -0.82%+4.59%+95.69%+140.86%

Financials

2026 *2027 *
Net sales 17.23M 11.95M 10.46M 9.64M 8.93M 16.96M 1.13B 116M 44.94M 560M 44.87M 43.9M 1.93B 3.15M 2.19M 1.91M 1.76M 1.63M 3.1M 207M 21.14M 8.22M 102M 8.21M 8.03M 354M
Net income -58.54M -40.6M -35.53M -32.74M -30.35M -57.61M -3.85B -393M -153M -1.9B -152M -149M -6.57B -47.05M -32.63M -28.56M -26.32M -24.39M -46.31M -3.1B -316M -123M -1.53B -123M -120M -5.28B
Net Debt -65.09M -45.14M -39.5M -36.41M -33.74M -64.06M -4.28B -437M -170M -2.11B -169M -166M -7.31B -77.26M -53.58M -46.89M -43.21M -40.05M -76.03M -5.09B -518M -202M -2.51B -201M -197M -8.67B
Logo Immutep Limited
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Employees
31
Date Price Change Volume
08/07/26 A$0.0530 -3.64% 7,019,166
07/07/26 A$0.0550 0.00% 19,487,912
06/07/26 A$0.0550 0.00% 2,914,012
03/07/26 A$0.0550 -1.79% 5,503,476
02/07/26 A$0.0560 -1.75% 6,319,163
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.0550AUD
Average target price
0.1033AUD
Spread / Average Target
+87.87%

Quarterly revenue - Rate of surprise